Uncontrolled prostate-cell growth; a common male cancer
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
The Celebrity Traitors has won best reality competition at the NTAs, with Alan Carr receiving a special recognition award. Paloma Faith staged a coffin entrance, while Carr reflected on the year’s achievements as the ceremony celebrated multiple categories.
The Independent reports Clarkson has announced remission after aggressive prostate cancer treatment with high-intensity ultrasound. He says he will continue checking annually, but he is choosing joy and life’s small pleasures. He also recently won a TV award for Clarkson’s Farm.
A new analysis shows a rise in cancers among people under 50 across England, the US and the Netherlands, driven by obesity, diet and lifestyle factors, with bowel, kidney and uterine cancers among the fastest-growing. Experts urge research and prevention as diagnosis at younger ages becomes more common.
The excerpt from President Biden's forthcoming memoir, Promise Me, America, published by The Atlantic, has the former president condemning Donald Trump’s actions on January 6, 2021 and criticizing pardons. Biden says the riot was not a peaceful protest and warns the episode should follow Trump to his grave. The memoir notes Biden’s cancer treatment while his promotional activity is limited.
The American Cancer Society has updated guidelines on PSA testing for prostate cancer. Average-risk men should begin screening at 50 with tests every two years until 69. Higher-risk groups, including Black men and those with a family history, should start at 45 with annual tests. The update emphasizes repeat testing to confirm high results and the possible use of MRI or biomarkers before biopsy. Continued screening after 70 is decision-based.